Ab s tra c t 23
Pharmacokinetic-pharmacodynamic (PK-PD) analyses for efficacy using Phase 3 data 24 from patients treated with ceftaroline fosamil 600 mg IV q12h for 5-7 days for In each of the above-described Phase 3 studies, patients received two consecutive 58 infusions of 300 mg IV ceftaroline fosamil q12h, each infused over 30 minutes for a total 59 dose of 600 mg and total infusion time of 60 minutes, with dose adjustments in patients 60 with moderate renal impairment. The total duration of treatment was 5 to 7 days.
61
Patients were eligible for inclusion if they were at least 18 years of age with CABP and if that only 28 CABP patients with PK data collected were in the ME population. In order 90 to utilize data for all patients with CABP in the ME population for the PK-PD analyses,
91
f %T>MIC values were also calculated for patients without PK data (n=96) using the 92 population PK models for ceftaroline fosamil and ceftaroline and patient covariate data 93 as prior information.
95
To support the use of population mean predicted f %T>MIC as a surrogate for individual 96 predicted f %T>MIC values, the bias and precision of these exposure measures were 97 examined for all patients with PK data by assessing the distribution of the percent 98 predicted error (PE%) and the absolute predicted error (|PE%|), respectively (10). PE% analyses were carried out using data from all of the ME patients (n=124). Thus, these data provide support for the adequacy of exposure of ceftaroline fosamil
